Page last updated: 2024-08-07 16:37:24
Kappa-type opioid receptor
A kappa-type opioid receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P41145]
Synonyms
K-OR-1;
KOR-1
Research
Bioassay Publications (317)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 7 (2.21) | 18.7374 |
| 1990's | 14 (4.42) | 18.2507 |
| 2000's | 131 (41.32) | 29.6817 |
| 2010's | 142 (44.79) | 24.3611 |
| 2020's | 23 (7.26) | 2.80 |
Compounds (194)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| bremazocine | Homo sapiens (human) | IC50 | 0.0008 | 2 | 3 |
| bremazocine | Homo sapiens (human) | Ki | 0.0000 | 1 | 1 |
| amiodarone | Homo sapiens (human) | IC50 | 16.6800 | 1 | 0 |
| amiodarone | Homo sapiens (human) | Ki | 6.6720 | 1 | 0 |
| astemizole | Homo sapiens (human) | IC50 | 6.6160 | 1 | 0 |
| astemizole | Homo sapiens (human) | Ki | 2.6460 | 1 | 0 |
| bisacodyl | Homo sapiens (human) | IC50 | 2.4370 | 1 | 0 |
| bisacodyl | Homo sapiens (human) | Ki | 0.9750 | 1 | 0 |
| chlorpromazine | Homo sapiens (human) | IC50 | 11.0820 | 1 | 0 |
| chlorpromazine | Homo sapiens (human) | Ki | 4.4330 | 1 | 0 |
| clotrimazole | Homo sapiens (human) | IC50 | 6.3030 | 1 | 0 |
| clotrimazole | Homo sapiens (human) | Ki | 2.5210 | 1 | 0 |
| disulfiram | Homo sapiens (human) | IC50 | 6.1030 | 1 | 0 |
| disulfiram | Homo sapiens (human) | Ki | 2.4410 | 1 | 0 |
| domperidone | Homo sapiens (human) | IC50 | 6.9940 | 1 | 0 |
| domperidone | Homo sapiens (human) | Ki | 2.7980 | 1 | 0 |
| econazole | Homo sapiens (human) | IC50 | 8.6160 | 1 | 0 |
| econazole | Homo sapiens (human) | Ki | 3.4460 | 1 | 0 |
| fentanyl | Homo sapiens (human) | IC50 | 1.5800 | 1 | 1 |
| fentanyl | Homo sapiens (human) | Ki | 0.1965 | 1 | 1 |
| fluphenazine | Homo sapiens (human) | IC50 | 24.7270 | 1 | 0 |
| fluphenazine | Homo sapiens (human) | Ki | 9.8910 | 1 | 0 |
| fluspirilene | Homo sapiens (human) | Ki | 0.5000 | 1 | 1 |
| gr 89696 | Homo sapiens (human) | IC50 | 0.0020 | 1 | 3 |
| gr 89696 | Homo sapiens (human) | Ki | 0.1802 | 2 | 2 |
| haloprogin | Homo sapiens (human) | IC50 | 1.1470 | 1 | 0 |
| haloprogin | Homo sapiens (human) | Ki | 0.4590 | 1 | 0 |
| ici 204448 | Homo sapiens (human) | Ki | 0.0027 | 1 | 1 |
| loperamide | Homo sapiens (human) | IC50 | 3.1250 | 1 | 0 |
| loperamide | Homo sapiens (human) | Ki | 1.2500 | 1 | 0 |
| meperidine | Homo sapiens (human) | IC50 | 14.2900 | 3 | 3 |
| methadone | Homo sapiens (human) | IC50 | 0.5120 | 1 | 1 |
| miconazole | Homo sapiens (human) | IC50 | 6.5940 | 1 | 0 |
| miconazole | Homo sapiens (human) | Ki | 2.6370 | 1 | 0 |
| propranolol | Homo sapiens (human) | IC50 | 5.0119 | 1 | 1 |
| raloxifene | Homo sapiens (human) | IC50 | 1.6020 | 1 | 0 |
| raloxifene | Homo sapiens (human) | Ki | 0.6410 | 1 | 0 |
| thioridazine | Homo sapiens (human) | IC50 | 2.4900 | 1 | 0 |
| thioridazine | Homo sapiens (human) | Ki | 0.9960 | 1 | 0 |
| ultram | Homo sapiens (human) | Ki | 0.0140 | 1 | 1 |
| ethinyl estradiol | Homo sapiens (human) | IC50 | 25.8940 | 1 | 0 |
| ethinyl estradiol | Homo sapiens (human) | Ki | 10.3580 | 1 | 0 |
| dibenzothiazyl disulfide | Homo sapiens (human) | IC50 | 1.2430 | 1 | 0 |
| dibenzothiazyl disulfide | Homo sapiens (human) | Ki | 0.4970 | 1 | 0 |
| indopan | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| gentian violet | Homo sapiens (human) | IC50 | 1.5400 | 1 | 0 |
| gentian violet | Homo sapiens (human) | Ki | 0.6160 | 1 | 0 |
| pimozide | Homo sapiens (human) | IC50 | 0.9900 | 1 | 1 |
| cyclazocine | Homo sapiens (human) | Ki | 0.0001 | 1 | 1 |
| danazol | Homo sapiens (human) | IC50 | 15.5180 | 1 | 0 |
| danazol | Homo sapiens (human) | Ki | 6.2070 | 1 | 0 |
| penfluridol | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
| tramadol | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| mifepristone | Homo sapiens (human) | IC50 | 20.0960 | 1 | 0 |
| mifepristone | Homo sapiens (human) | Ki | 8.0380 | 1 | 0 |
| spiradoline | Homo sapiens (human) | IC50 | 0.0083 | 1 | 0 |
| spiradoline | Homo sapiens (human) | Ki | 0.0033 | 1 | 0 |
| enadoline | Homo sapiens (human) | Ki | 0.0003 | 1 | 1 |
| carfentanil | Homo sapiens (human) | Ki | 0.0431 | 1 | 1 |
| nelfinavir | Homo sapiens (human) | IC50 | 35.9960 | 1 | 0 |
| nelfinavir | Homo sapiens (human) | Ki | 14.3980 | 1 | 0 |
| loperamide hydrochloride | Homo sapiens (human) | IC50 | 0.1550 | 1 | 1 |
| enkephalin, d-penicillamine (2,5)- | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| vanoxerine | Homo sapiens (human) | IC50 | 2.1400 | 1 | 1 |
| u 69593 | Homo sapiens (human) | IC50 | 0.0580 | 4 | 5 |
| u 69593 | Homo sapiens (human) | Ki | 0.2420 | 13 | 38 |
| gr 127935 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| tifluadom | Homo sapiens (human) | Ki | 0.0002 | 1 | 1 |
| bw 373u86 | Homo sapiens (human) | IC50 | 0.0200 | 1 | 1 |
| bw 373u86 | Homo sapiens (human) | Ki | 1.7650 | 2 | 2 |
| enkephalin-leu, arg(6)- | Homo sapiens (human) | Ki | 0.4040 | 1 | 1 |
| tyrosyl-arginyl-phenylalanyl-lysinamide | Homo sapiens (human) | Ki | 4.2300 | 1 | 1 |
| met-enkephalinamide | Homo sapiens (human) | Ki | 0.2100 | 1 | 1 |
| 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide | Homo sapiens (human) | IC50 | 2.4800 | 2 | 2 |
| 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide | Homo sapiens (human) | Ki | 3.7463 | 3 | 3 |
| 4-methoxymethylfentanyl | Homo sapiens (human) | Ki | 0.0630 | 1 | 1 |
| salvinorin a | Homo sapiens (human) | Ki | 0.3451 | 20 | 49 |
| ly 99335, (3r-cis)-isomer | Homo sapiens (human) | Ki | 0.8330 | 1 | 1 |
| ly 106737 | Homo sapiens (human) | Ki | 0.0255 | 6 | 6 |
| 3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer | Homo sapiens (human) | Ki | 0.0014 | 4 | 4 |
| nantenine, (+-)-isomer | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| n-methyl-n-(1-phenyl-2-(1-pyrrolidinyl)ethyl)phenylacetamide | Homo sapiens (human) | Ki | 0.0058 | 1 | 1 |
| ritonavir | Homo sapiens (human) | IC50 | 13.6550 | 1 | 0 |
| ritonavir | Homo sapiens (human) | Ki | 5.4620 | 1 | 0 |
| saquinavir | Homo sapiens (human) | IC50 | 6.9510 | 1 | 0 |
| saquinavir | Homo sapiens (human) | Ki | 2.7800 | 1 | 0 |
| pentazocine | Homo sapiens (human) | Ki | 0.0022 | 1 | 1 |
| enkephalin, methionine | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| diprenorphine | Homo sapiens (human) | Ki | 0.0003 | 5 | 5 |
| diethylstilbestrol | Homo sapiens (human) | IC50 | 4.5630 | 1 | 0 |
| diethylstilbestrol | Homo sapiens (human) | Ki | 1.8250 | 1 | 0 |
| enkephalin, leucine | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
| cannabidiol | Homo sapiens (human) | Ki | 2.3000 | 1 | 1 |
| buprenorphine | Homo sapiens (human) | Ki | 0.0000 | 1 | 1 |
| etorphine | Homo sapiens (human) | Ki | 0.0005 | 2 | 2 |
| tamoxifen | Homo sapiens (human) | IC50 | 15.6290 | 1 | 0 |
| tamoxifen | Homo sapiens (human) | Ki | 6.2520 | 1 | 0 |
| hirsutine, (16e,20beta)-isomer | Homo sapiens (human) | Ki | 1.9100 | 1 | 1 |
| mitragynine | Homo sapiens (human) | Ki | 0.4850 | 2 | 2 |
| u-50488 | Homo sapiens (human) | IC50 | 0.0537 | 13 | 14 |
| u-50488 | Homo sapiens (human) | Ki | 0.0083 | 25 | 26 |
| paynantheine | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| paynantheine | Homo sapiens (human) | Ki | 2.5600 | 1 | 1 |
| metazocine | Homo sapiens (human) | Ki | 0.0099 | 1 | 1 |
| dynorphin (1-17) | Homo sapiens (human) | Ki | 0.0025 | 1 | 1 |
| ici 199441 | Homo sapiens (human) | Ki | 0.0000 | 4 | 4 |
| dynorphin (1-11) | Homo sapiens (human) | IC50 | 0.0066 | 2 | 2 |
| dynorphin (1-11) | Homo sapiens (human) | Ki | 0.0001 | 1 | 1 |
| 4-[[(4-methylphenyl)sulfonylamino]methyl]-N-[2-[(phenylmethyl)-propan-2-ylamino]ethyl]benzamide | Homo sapiens (human) | IC50 | 0.6187 | 6 | 6 |
| brl 52537 | Homo sapiens (human) | IC50 | 0.0110 | 1 | 1 |
| flunarizine hydrochloride | Homo sapiens (human) | IC50 | 9.4800 | 1 | 1 |
| codeine | Homo sapiens (human) | IC50 | 15.0000 | 1 | 1 |
| codeine | Homo sapiens (human) | Ki | 25.4110 | 1 | 1 |
| hydrocodone | Homo sapiens (human) | Ki | 0.2600 | 1 | 1 |
| hydromorphone | Homo sapiens (human) | Ki | 0.0028 | 1 | 1 |
| nalmefene | Homo sapiens (human) | Ki | 0.0006 | 4 | 4 |
| nalorphine | Homo sapiens (human) | Ki | 0.0012 | 2 | 2 |
| naloxone | Homo sapiens (human) | IC50 | 0.0796 | 8 | 7 |
| naloxone | Homo sapiens (human) | Ki | 0.0321 | 16 | 15 |
| oxymorphone | Homo sapiens (human) | Ki | 0.0253 | 1 | 1 |
| morphine | Homo sapiens (human) | IC50 | 0.6550 | 3 | 3 |
| morphine | Homo sapiens (human) | Ki | 0.1098 | 26 | 26 |
| 7-benzylidenenaltrexone | Homo sapiens (human) | Ki | 0.0306 | 2 | 2 |
| alpha-neoendorphin | Homo sapiens (human) | Ki | 0.0024 | 1 | 1 |
| beta-funaltrexamine | Homo sapiens (human) | Ki | 0.0009 | 2 | 2 |
| endomorphin 1 | Homo sapiens (human) | Ki | 2.4412 | 3 | 5 |
| endomorphin 2 | Homo sapiens (human) | Ki | 1.1513 | 4 | 6 |
| j 113397 | Homo sapiens (human) | IC50 | 1.5000 | 2 | 2 |
| j 113397 | Homo sapiens (human) | Ki | 0.4000 | 1 | 1 |
| l 745870 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| nalbuphine | Homo sapiens (human) | IC50 | 0.0970 | 2 | 1 |
| nalbuphine | Homo sapiens (human) | Ki | 0.0164 | 3 | 2 |
| n-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide | Homo sapiens (human) | IC50 | 7.5120 | 1 | 1 |
| n-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide | Homo sapiens (human) | Ki | 1.0572 | 2 | 2 |
| notopterol | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| levorphanol | Homo sapiens (human) | IC50 | 0.0040 | 1 | 1 |
| levorphanol | Homo sapiens (human) | Ki | 0.0023 | 6 | 6 |
| cyclorphan | Homo sapiens (human) | Ki | 0.0000 | 8 | 8 |
| naltrexone | Homo sapiens (human) | IC50 | 0.0377 | 8 | 9 |
| naltrexone | Homo sapiens (human) | Ki | 0.0024 | 28 | 29 |
| butorphanol | Homo sapiens (human) | Ki | 0.0002 | 3 | 3 |
| methylnaltrexone | Homo sapiens (human) | Ki | 0.0321 | 1 | 1 |
| enkephalin, ala(2)-mephe(4)-gly(5)- | Homo sapiens (human) | Ki | 3.4116 | 7 | 7 |
| naloxone hydrochloride | Homo sapiens (human) | IC50 | 0.0049 | 2 | 2 |
| norbinaltorphimine | Homo sapiens (human) | IC50 | 0.0036 | 7 | 7 |
| norbinaltorphimine | Homo sapiens (human) | Ki | 0.0013 | 24 | 24 |
| dermorphin | Homo sapiens (human) | Ki | 8.1620 | 1 | 1 |
| naltrexone hydrochloride | Homo sapiens (human) | IC50 | 0.0006 | 2 | 2 |
| 6 beta-hydroxynaltrexone | Homo sapiens (human) | IC50 | 0.0083 | 2 | 5 |
| 6 beta-hydroxynaltrexone | Homo sapiens (human) | Ki | 0.0005 | 1 | 1 |
| 14-methoxymetopon | Homo sapiens (human) | Ki | 0.1148 | 3 | 3 |
| biphalin | Homo sapiens (human) | Ki | 0.2700 | 1 | 1 |
| alvimopan anhydrous | Homo sapiens (human) | Ki | 0.1000 | 1 | 1 |
| tyrosyl alanyl-glycyl-phenylalaninamide | Homo sapiens (human) | IC50 | 0.2239 | 1 | 1 |
| oxymorphindole | Homo sapiens (human) | Ki | 0.4555 | 2 | 2 |
| naltrindole | Homo sapiens (human) | Ki | 0.0169 | 12 | 12 |
| trk 820 | Homo sapiens (human) | Ki | 0.0426 | 4 | 4 |
| clocinnamox | Homo sapiens (human) | IC50 | 0.0001 | 1 | 1 |
| clocinnamox | Homo sapiens (human) | Ki | 0.0014 | 4 | 4 |
| gr 103545 | Homo sapiens (human) | Ki | 0.0005 | 1 | 1 |
| 3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(-)-isomer | Homo sapiens (human) | Ki | 0.1730 | 2 | 2 |
| nalfurafine hydrochloride | Homo sapiens (human) | Ki | 0.0002 | 1 | 1 |
| naloxonazine | Homo sapiens (human) | IC50 | 0.0850 | 1 | 0 |
| naloxonazine | Homo sapiens (human) | Ki | 0.0340 | 1 | 0 |
| sodium selenate | Homo sapiens (human) | Ki | 0.0001 | 15 | 15 |
| 17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan | Homo sapiens (human) | Ki | 0.0001 | 3 | 3 |
| o-demethyltramadol | Homo sapiens (human) | Ki | 5.2250 | 2 | 2 |
| ro 64-6198 | Homo sapiens (human) | Ki | 0.4000 | 1 | 1 |
| sr 14150 | Homo sapiens (human) | Ki | 0.0427 | 2 | 2 |
| ly 255582 | Homo sapiens (human) | Ki | 0.0036 | 4 | 4 |
| 4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
| sb-612111 | Homo sapiens (human) | Ki | 0.4000 | 1 | 1 |
| deltorphin i, ala(2)- | Homo sapiens (human) | IC50 | 7.3300 | 1 | 1 |
| 8-carboxamidocyclazocine | Homo sapiens (human) | Ki | 0.0001 | 3 | 3 |
| akuammicine | Homo sapiens (human) | Ki | 0.0842 | 1 | 2 |
| 6-deoxy-6-fluoronaltrexone | Homo sapiens (human) | IC50 | 0.0079 | 1 | 1 |
| dynorphin (1-17) | Homo sapiens (human) | Ki | 0.0046 | 1 | 1 |
| dynorphin a (1-11)-amide | Homo sapiens (human) | IC50 | 0.0002 | 1 | 1 |
| dynorphin a (1-11)-amide | Homo sapiens (human) | Ki | 0.0001 | 3 | 3 |
| amd 070 | Homo sapiens (human) | IC50 | 30.0000 | 1 | 1 |
| mesyl salvinorin b | Homo sapiens (human) | Ki | 0.0023 | 2 | 2 |
| naluzotan | Homo sapiens (human) | Ki | 2.0000 | 1 | 1 |
| 9-(benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2h-naphtho(2,1-c)pyran-7-carboxylic acid methyl ester | Homo sapiens (human) | Ki | 0.0900 | 3 | 3 |
| salvinorin b | Homo sapiens (human) | Ki | 1.8118 | 6 | 6 |
| way 207024 | Homo sapiens (human) | Ki | 0.5500 | 1 | 1 |
| 14-o-methyloxymorphone | Homo sapiens (human) | Ki | 0.0101 | 1 | 1 |
| mitragynine, (3beta,16e,20beta)-isomer | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| mitragynine, (3beta,16e,20beta)-isomer | Homo sapiens (human) | Ki | 0.2225 | 2 | 2 |
| mitragynine | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| mitragynine | Homo sapiens (human) | Ki | 3.2000 | 1 | 1 |
| a 803467 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| morphine sulfate | Homo sapiens (human) | IC50 | 0.1205 | 2 | 2 |
| nociceptin | Homo sapiens (human) | Ki | 2.6078 | 6 | 6 |
| dynorphin (1-17) | Homo sapiens (human) | Ki | 0.0002 | 1 | 1 |
| sp 203 | Homo sapiens (human) | Ki | 10.0000 | 1 | 1 |
| 1-(1-(1-methylcyclooctyl)-4-piperidinyl)-2-((3r)-3-piperidinyl)-1h-benzimidazole | Homo sapiens (human) | Ki | 0.0231 | 1 | 1 |
| salvinorin b ethoxymethyl ether | Homo sapiens (human) | Ki | 0.0017 | 2 | 2 |
| dynorphins | Homo sapiens (human) | IC50 | 0.0001 | 1 | 1 |
| dynorphins | Homo sapiens (human) | Ki | 0.2835 | 3 | 28 |
| ly2456302 | Homo sapiens (human) | Ki | 0.0008 | 3 | 3 |
| 7-hydroxymitragynine | Homo sapiens (human) | Ki | 0.0741 | 1 | 1 |
| mitragynine pseudoindoxyl | Homo sapiens (human) | IC50 | 0.1318 | 2 | 2 |
| mitragynine pseudoindoxyl | Homo sapiens (human) | Ki | 0.0790 | 1 | 1 |
| 7-spiroindanyloxymorphone | Homo sapiens (human) | Ki | 1.5770 | 2 | 2 |
| gsk 1059865 | Homo sapiens (human) | Ki | 0.3200 | 1 | 1 |
| nitd 609 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| cj 15,208 | Homo sapiens (human) | IC50 | 0.2435 | 2 | 2 |
| cj 15,208 | Homo sapiens (human) | Ki | 0.0305 | 2 | 2 |
| pf-04455242 | Homo sapiens (human) | Ki | 0.0018 | 3 | 3 |
| 2-[5-[(3,4-dichlorophenyl)methylthio]-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]pyridine | Homo sapiens (human) | Ki | 0.0403 | 1 | 1 |
| 4-[[(4-ethylphenyl)sulfonylamino]methyl]-N-[2-[(phenylmethyl)-propan-2-ylamino]ethyl]benzamide | Homo sapiens (human) | IC50 | 1.8350 | 2 | 2 |
| LSM-2536 | Homo sapiens (human) | IC50 | 0.0810 | 3 | 3 |
| n,n-diallyl-5-methoxytryptamine | Homo sapiens (human) | Ki | 7.0407 | 2 | 3 |
| 3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)phenol | Homo sapiens (human) | Ki | 0.0005 | 1 | 1 |
| 22-thiocyanatosalvinorin a | Homo sapiens (human) | Ki | 0.0006 | 2 | 2 |
Drugs with Activation Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid | Homo sapiens (human) | EC50 | 100.0000 | 1 | 1 |
| propranolol | Homo sapiens (human) | EC50 | 5.0119 | 1 | 1 |
| suramin | Homo sapiens (human) | EC50 | 100.0000 | 1 | 1 |
| adenosine diphosphate | Homo sapiens (human) | EC50 | 11.0000 | 1 | 1 |
| spiradoline | Homo sapiens (human) | EC50 | 0.0180 | 1 | 1 |
| alpha,beta-methyleneadenosine 5'-triphosphate | Homo sapiens (human) | EC50 | 8.0000 | 1 | 1 |
| u 69593 | Homo sapiens (human) | EC50 | 0.1892 | 31 | 56 |
| 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide | Homo sapiens (human) | EC50 | 5.2640 | 1 | 1 |
| 4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-n,n-diethylbenzamide | Homo sapiens (human) | Kd | 0.6290 | 1 | 1 |
| salvinorin a | Homo sapiens (human) | EC50 | 0.0184 | 33 | 60 |
| 3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer | Homo sapiens (human) | EC50 | 0.0076 | 2 | 2 |
| asimadoline | Homo sapiens (human) | EC50 | 0.0005 | 1 | 1 |
| n-methyl-n-(1-phenyl-2-(1-pyrrolidinyl)ethyl)phenylacetamide | Homo sapiens (human) | EC50 | 0.0500 | 1 | 1 |
| adenosine 5'-o-(3-thiotriphosphate) | Homo sapiens (human) | EC50 | 1.3000 | 1 | 1 |
| diprenorphine | Homo sapiens (human) | Kd | 0.0023 | 1 | 26 |
| enkephalin, leucine | Homo sapiens (human) | EC50 | 0.0800 | 3 | 3 |
| 4-methyl-N-[1-[2-(1-pyrrolidinyl)ethyl]-2-benzimidazolyl]benzamide | Homo sapiens (human) | EC50 | 0.0390 | 1 | 1 |
| mitragynine | Homo sapiens (human) | EC50 | 8.5000 | 1 | 1 |
| u-50488 | Homo sapiens (human) | EC50 | 0.0416 | 32 | 32 |
| metazocine | Homo sapiens (human) | EC50 | 0.1200 | 1 | 1 |
| ketazocine | Homo sapiens (human) | EC50 | 0.0033 | 1 | 1 |
| ici 199441 | Homo sapiens (human) | EC50 | 0.0003 | 3 | 3 |
| hydromorphone | Homo sapiens (human) | EC50 | 0.0110 | 1 | 1 |
| naloxone | Homo sapiens (human) | EC50 | 0.0083 | 2 | 2 |
| naloxone | Homo sapiens (human) | Kd | 0.0010 | 1 | 1 |
| oxycodone | Homo sapiens (human) | EC50 | 16.0000 | 1 | 1 |
| morphine | Homo sapiens (human) | EC50 | 0.4443 | 6 | 6 |
| 2-methylthio-atp | Homo sapiens (human) | EC50 | 0.6000 | 1 | 1 |
| nalbuphine | Homo sapiens (human) | EC50 | 0.0995 | 4 | 4 |
| dihydromorphine | Homo sapiens (human) | Kd | 0.8300 | 1 | 1 |
| cyclorphan | Homo sapiens (human) | EC50 | 0.0002 | 7 | 7 |
| naltrexone | Homo sapiens (human) | EC50 | 0.0020 | 3 | 3 |
| butorphanol | Homo sapiens (human) | EC50 | 0.0029 | 1 | 1 |
| methylnaltrexone | Homo sapiens (human) | EC50 | 10.0000 | 1 | 1 |
| enkephalin, ala(2)-mephe(4)-gly(5)- | Homo sapiens (human) | EC50 | 6.1217 | 3 | 3 |
| norbinaltorphimine | Homo sapiens (human) | EC50 | 0.0060 | 1 | 1 |
| naltrindole | Homo sapiens (human) | EC50 | 0.0050 | 1 | 1 |
| cyprodime | Homo sapiens (human) | EC50 | 0.1170 | 1 | 1 |
| trk 820 | Homo sapiens (human) | EC50 | 0.0223 | 5 | 5 |
| 3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(-)-isomer | Homo sapiens (human) | EC50 | 0.0313 | 3 | 3 |
| enkephalin, leucine-2-alanine | Homo sapiens (human) | Kd | 0.6250 | 1 | 1 |
| nalfurafine hydrochloride | Homo sapiens (human) | EC50 | 0.0000 | 2 | 2 |
| sodium selenate | Homo sapiens (human) | EC50 | 0.0013 | 8 | 8 |
| 17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5'-guanidinyl-3,14-dihydroxyindolo(2',3'-6,7)morphinan | Homo sapiens (human) | Kd | 0.0000 | 1 | 1 |
| sr 14150 | Homo sapiens (human) | EC50 | 0.2760 | 1 | 1 |
| 6'-guanidinonaltrindole | Homo sapiens (human) | EC50 | 0.0014 | 2 | 2 |
| 8-carboxamidocyclazocine | Homo sapiens (human) | EC50 | 0.0044 | 2 | 2 |
| akuammicine | Homo sapiens (human) | EC50 | 39.8107 | 1 | 1 |
| dynorphin a (1-11)-amide | Homo sapiens (human) | EC50 | 0.0007 | 2 | 2 |
| mesyl salvinorin b | Homo sapiens (human) | EC50 | 0.0300 | 1 | 1 |
| 9-(benzoyloxy)-2-(3-furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-2h-naphtho(2,1-c)pyran-7-carboxylic acid methyl ester | Homo sapiens (human) | EC50 | 0.9367 | 3 | 3 |
| salvinorin b | Homo sapiens (human) | EC50 | 0.1862 | 4 | 4 |
| 14-o-methyloxymorphone | Homo sapiens (human) | EC50 | 0.1160 | 1 | 1 |
| nociceptin | Homo sapiens (human) | EC50 | 0.0785 | 1 | 1 |
| dynorphin (1-17) | Homo sapiens (human) | EC50 | 0.0024 | 4 | 4 |
| 1-(1-(1-methylcyclooctyl)-4-piperidinyl)-2-((3r)-3-piperidinyl)-1h-benzimidazole | Homo sapiens (human) | EC50 | 0.0800 | 1 | 1 |
| salvinorin b ethoxymethyl ether | Homo sapiens (human) | EC50 | 0.0001 | 1 | 1 |
| dynorphins | Homo sapiens (human) | EC50 | 0.1169 | 4 | 28 |
| mitragynine pseudoindoxyl | Homo sapiens (human) | EC50 | 0.0017 | 2 | 2 |
| 2-[5-[(3,4-dichlorophenyl)methylthio]-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]pyridine | Homo sapiens (human) | EC50 | 37.6825 | 4 | 4 |
| trv130 | Homo sapiens (human) | EC50 | 5.7000 | 2 | 2 |
| 3-(2-((cyclobutylmethyl)(phenethyl)amino)ethyl)phenol | Homo sapiens (human) | EC50 | 0.1572 | 3 | 3 |
| 22-thiocyanatosalvinorin a | Homo sapiens (human) | EC50 | 0.2838 | 4 | 4 |
| 22-thiocyanatosalvinorin a | Homo sapiens (human) | Kd | 0.0006 | 1 | 1 |
Drugs with Other Measurements
Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists.Bioorganic & medicinal chemistry, , Jun-15, Volume: 18, Issue:12, 2010
Electrophilic opioid ligands. Oxygen tethered alpha-methylene-gamma-lactone, acrylate, isothiocyanate, and epoxide derivatives of 6 beta-naltrexol.Journal of medicinal chemistry, , Jun-26, Volume: 35, Issue:13, 1992
Conjugate addition ligands of opioid antagonists. Methacrylate esters and ethers of 6 alpha- and 6 beta-naltrexol.Journal of medicinal chemistry, , Volume: 33, Issue:2, 1990
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.Journal of medicinal chemistry, , Oct-11, Volume: 44, Issue:21, 2001
Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Conformationally restricted κ-opioid receptor agonists: Synthesis and pharmacological evaluation of diastereoisomeric and enantiomeric decahydroquinoxalines.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 25, Issue:22, 2015
Synthesis of 7,9-diazabicyclo[4.2.2]decanes as conformationally restricted κ receptor agonists: fine tuning of the dihedral angle of the ethylenediamine pharmacophore.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
A potent new class of kappa-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines.Journal of medicinal chemistry, , Jul-23, Volume: 36, Issue:15, 1993
Morphinan derivatives with an oxabicyclo[3.2.1]octane structure as dual agonists toward δ and κ opioid receptors.Bioorganic & medicinal chemistry, , 01-01, Volume: 53, 2022
[no title available]European journal of medicinal chemistry, , Jan-15, Volume: 228, 2022
Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects.Journal of medicinal chemistry, , 09-23, Volume: 64, Issue:18, 2021
O6C-20-nor-salvinorin A is a stable and potent KOR agonist.Bioorganic & medicinal chemistry letters, , 09-01, Volume: 28, Issue:16, 2018
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
Design and Synthesis of Enantiomerically Pure Decahydroquinoxalines as Potent and Selective κ-Opioid Receptor Agonists with Anti-Inflammatory Activity in Vivo.Journal of medicinal chemistry, , 03-23, Volume: 60, Issue:6, 2017
Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.Bioorganic & medicinal chemistry letters, , 02-01, Volume: 27, Issue:3, 2017
Probes for narcotic receptor mediated phenomena 49. N-substituted rac-cis-4a-arylalkyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.European journal of medicinal chemistry, , Mar-06, Volume: 92, 2015
Synthesis of new opioid derivatives with a propellane skeleton and their pharmacologies: Part 5, novel pentacyclic propellane derivatives with a 6-amide side chain.Bioorganic & medicinal chemistry, , Oct-01, Volume: 23, Issue:19, 2015
Synthesis and Pharmacology of a Novel κ Opioid Receptor (KOR) Agonist with a 1,3,5-Trioxazatriquinane Skeleton.ACS medicinal chemistry letters, , Aug-14, Volume: 5, Issue:8, 2014
Design, synthesis, and structure-activity relationship of novel opioid κ receptor selective agonists: α-iminoamide derivatives with an azabicyclo[2.2.2]octene skeleton.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 24, Issue:21, 2014
Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues.Journal of medicinal chemistry, , Dec-26, Volume: 57, Issue:24, 2014
Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.Bioorganic & medicinal chemistry, , Apr-15, Volume: 22, Issue:8, 2014
Synthesis and pharmacological evaluation of 5-pyrrolidinylquinoxalines as a novel class of peripherally restricted κ-opioid receptor agonists.Journal of medicinal chemistry, , Aug-14, Volume: 57, Issue:15, 2014
Synthesis of a novel universal opioid receptor agonist with the 1,3,5-trioxazatriquinane skeleton and its pharmacologies.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 24, Issue:20, 2014
Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity.Bioorganic & medicinal chemistry, , Apr-01, Volume: 22, Issue:7, 2014
Combination of cyclohexane and piperazine based κ-opioid receptor agonists: Synthesis and pharmacological evaluation of trans,trans-configured perhydroquinoxalines.Bioorganic & medicinal chemistry, , Jul-01, Volume: 22, Issue:13, 2014
The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 23, Issue:1, 2013
Probes for narcotic receptor mediated phenomena. 48. C7- and C8-substituted 5-phenylmorphan opioids from diastereoselective alkylation.European journal of medicinal chemistry, , Volume: 67, 2013
Chemotype-selective modes of action of κ-opioid receptor agonists.The Journal of biological chemistry, , Nov-29, Volume: 288, Issue:48, 2013
Probes for narcotic receptor mediated phenomena. 47. Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.Bioorganic & medicinal chemistry, , Jun-01, Volume: 21, Issue:11, 2013
Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012
Semisynthetic neoclerodanes as kappa opioid receptor probes.Bioorganic & medicinal chemistry, , May-01, Volume: 20, Issue:9, 2012
Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity.European journal of medicinal chemistry, , Volume: 50, 2012
Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.Journal of medicinal chemistry, , Oct-13, Volume: 54, Issue:19, 2011
Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists.Bioorganic & medicinal chemistry, , Jun-15, Volume: 18, Issue:12, 2010
Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica.Journal of natural products, , May-28, Volume: 73, Issue:5, 2010
Conformationally constrained kappa receptor agonists: stereoselective synthesis and pharmacological evaluation of 6,8-diazabicyclo[3.2.2]nonane derivatives.Journal of medicinal chemistry, , May-27, Volume: 53, Issue:10, 2010
Structure-antitussive activity relationships of naltrindole derivatives. Identification of novel and potent antitussive agents.Journal of medicinal chemistry, , Aug-14, Volume: 51, Issue:15, 2008
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.Journal of medicinal chemistry, , Jul-26, Volume: 50, Issue:15, 2007
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 17, Issue:22, 2007
A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 16, Issue:13, 2006
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.Journal of natural products, , Volume: 69, Issue:1, 2006
Synthesis and Biological activity of kappa opioid receptor agonists. Part 2: preparation of 3-aryl-2-pyridone analogues generated by solution- and solid-phase parallel synthesis methods.Bioorganic & medicinal chemistry letters, , Mar-24, Volume: 13, Issue:6, 2003
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.Journal of medicinal chemistry, , Apr-10, Volume: 46, Issue:8, 2003
Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003
3-Aryl pyridone derivatives. Potent and selective kappa opioid receptor agonists.Bioorganic & medicinal chemistry letters, , Jan-21, Volume: 12, Issue:2, 2002
Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the kappa-opioid receptor does not affect dynorphin A(1-13) affinity and function.Journal of medicinal chemistry, , Apr-06, Volume: 43, Issue:7, 2000
Isothiocyanate-substituted benzyl ether opioid receptor ligands derived from 6 beta-naltrexol.Journal of medicinal chemistry, , Feb-03, Volume: 38, Issue:3, 1995
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5859).Journal of medicinal chemistry, , Oct-09, Volume: 51, Issue:19, 2008
New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability.Journal of medicinal chemistry, , Oct-19, Volume: 43, Issue:21, 2000
Novel delta opioid receptor agonists with oxazatricyclodecane structure.ACS medicinal chemistry letters, , Apr-10, Volume: 5, Issue:4, 2014
N,N-Diethyl-4-[(3-hydroxyphenyl)(piperidin-4-yl)amino] benzamide derivatives: the development of diaryl amino piperidines as potent delta opioid receptor agonists with in vivo anti-nociceptive activity in rodent models.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 19, Issue:21, 2009
N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues.Journal of medicinal chemistry, , Oct-19, Volume: 43, Issue:21, 2000
New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability.Journal of medicinal chemistry, , Oct-19, Volume: 43, Issue:21, 2000
(+/-)-4-[(N-allyl-cis-3-methyl-4-piperidinyl)phenylamino]-N,N-diethylbenzamide displays selective binding for the delta opioid receptor.Bioorganic & medicinal chemistry letters, , Oct-18, Volume: 9, Issue:20, 1999
Optically pure (-)-4-[(N-allyl-3-methyl-4-piperidinyl)phenyl-amino]-N,N-diethylbenzami de displays selective binding and full agonist activity for the delta opioid receptor.Bioorganic & medicinal chemistry letters, , Dec-06, Volume: 9, Issue:23, 1999
G-Protein biased opioid agonists: 3-hydroxy-RSC medicinal chemistry, , Aug-01, Volume: 11, Issue:8, 2020
Development of Novel Quinoxaline-Based κ-Opioid Receptor Agonists for the Treatment of Neuroinflammation.Journal of medicinal chemistry, , 01-24, Volume: 62, Issue:2, 2019
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.Journal of medicinal chemistry, , 05-11, Volume: 60, Issue:9, 2017
Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene.Journal of natural products, , 07-28, Volume: 80, Issue:7, 2017
Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.Journal of medicinal chemistry, , 12-22, Volume: 59, Issue:24, 2016
Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 25, Issue:20, 2015
Studies toward the Development of Antiproliferative Neoclerodanes from Salvinorin A.Journal of natural products, , Aug-22, Volume: 77, Issue:8, 2014
The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 24, Issue:2, 2014
Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues.Journal of medicinal chemistry, , Dec-26, Volume: 57, Issue:24, 2014
Synthesis of a novel universal opioid receptor agonist with the 1,3,5-trioxazatriquinane skeleton and its pharmacologies.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 24, Issue:20, 2014
A perspective on natural products research and ethnopharmacology in Mexico: the eagle and the serpent on the prickly pear cactus.Journal of natural products, , Mar-28, Volume: 77, Issue:3, 2014
Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor.European journal of medicinal chemistry, , Oct-06, Volume: 85, 2014
Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
Chemotype-selective modes of action of κ-opioid receptor agonists.The Journal of biological chemistry, , Nov-29, Volume: 288, Issue:48, 2013
Semisynthetic neoclerodanes as kappa opioid receptor probes.Bioorganic & medicinal chemistry, , May-01, Volume: 20, Issue:9, 2012
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Synthesis and biological evaluation of new salvinorin A analogues incorporating natural amino acids.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 21, Issue:1, 2011
Opioid receptor probes derived from cycloaddition of the hallucinogen natural product salvinorin A.Journal of natural products, , Apr-25, Volume: 74, Issue:4, 2011
Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists.Bioorganic & medicinal chemistry, , Jun-15, Volume: 18, Issue:12, 2010
Synthesis and biological evaluation of C-2 halogenated analogs of salvinorin A.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 20, Issue:19, 2010
Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.Bioorganic & medicinal chemistry, , Feb-01, Volume: 17, Issue:3, 2009
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.Bioorganic & medicinal chemistry, , Sep-15, Volume: 17, Issue:18, 2009
Herkinorin analogues with differential beta-arrestin-2 interactions.Journal of medicinal chemistry, , Apr-24, Volume: 51, Issue:8, 2008
Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.Bioorganic & medicinal chemistry, , Feb-01, Volume: 16, Issue:3, 2008
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.Journal of medicinal chemistry, , Jul-26, Volume: 50, Issue:15, 2007
Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 17, Issue:8, 2007
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 17, Issue:22, 2007
Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18).Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 16, Issue:17, 2006
Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 16, Issue:21, 2006
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.Journal of natural products, , Volume: 69, Issue:1, 2006
Synthesis of salvinorin A analogues as opioid receptor probes.Journal of natural products, , Volume: 69, Issue:6, 2006
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.Journal of medicinal chemistry, , Jul-28, Volume: 48, Issue:15, 2005
Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2).Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Effect of the 3- and 4-methyl groups on the opioid receptor properties of N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines.Journal of medicinal chemistry, , Apr-10, Volume: 57, Issue:7, 2014
1-Substituted 4-(3-Hydroxyphenyl)piperazines Are Pure Opioid Receptor Antagonists.ACS medicinal chemistry letters, , Oct-14, Volume: 1, Issue:7, 2010
N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.Journal of medicinal chemistry, , Oct-08, Volume: 41, Issue:21, 1998
Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists.Journal of medicinal chemistry, , Dec-14, Volume: 49, Issue:25, 2006
Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.Journal of medicinal chemistry, , Dec-14, Volume: 49, Issue:25, 2006
Synthesis and structure-activity relationships of a new series of 2alpha-substituted trans-4,5-dimethyl-4-(3-hydroxyphenyl)piperidine as mu-selective opioid antagonists.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 16, Issue:4, 2006
trans-3,4-dimethyl-4-(3-carboxamidophenyl)piperidines: a novel class of micro-selective opioid antagonists.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 13, Issue:24, 2003
N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.Journal of medicinal chemistry, , Oct-08, Volume: 41, Issue:21, 1998
Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 25, Issue:20, 2015
Generation of novel radiolabeled opiates through site-selective iodination.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 21, Issue:13, 2011
Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues.Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 15, Issue:16, 2005
Development of Novel Quinoxaline-Based κ-Opioid Receptor Agonists for the Treatment of Neuroinflammation.Journal of medicinal chemistry, , 01-24, Volume: 62, Issue:2, 2019
Synthesis and evaluation of three structurally related ¹⁸F-labeled orvinols of different intrinsic activities: 6-O-[¹⁸F]fluoroethyl-diprenorphine ([¹⁸F]FDPN), 6-O-[¹⁸F]fluoroethyl-buprenorphine ([¹⁸F]FBPN), and 6-O-[¹⁸F]fluoroethyl-phenethyl-orvinol ([¹⁸FJournal of medicinal chemistry, , Jun-26, Volume: 57, Issue:12, 2014
Chemotype-selective modes of action of κ-opioid receptor agonists.The Journal of biological chemistry, , Nov-29, Volume: 288, Issue:48, 2013
Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists.Journal of medicinal chemistry, , Apr-20, Volume: 43, Issue:8, 2000
Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.Journal of medicinal chemistry, , 11-12, Volume: 63, Issue:21, 2020
Applications of amide isosteres in medicinal chemistry.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 29, Issue:18, 2019
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.Journal of medicinal chemistry, , 07-26, Volume: 61, Issue:14, 2018
Structure-activity relationships of dynorphin a analogues modified in the address sequence.Journal of medicinal chemistry, , May-22, Volume: 46, Issue:11, 2003
Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 25, Issue:20, 2015
Synthesis and biological evaluation of C-12 triazole and oxadiazole analogs of salvinorin A.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 19, Issue:5, 2009
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.Journal of medicinal chemistry, , 02-10, Volume: 65, Issue:3, 2022
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.Journal of medicinal chemistry, , 01-09, Volume: 63, Issue:1, 2020
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.Bioorganic & medicinal chemistry letters, , 09-15, Volume: 72, 2022
Isolation and Pharmacological Characterization of Six Opioidergic Journal of natural products, , 01-22, Volume: 84, Issue:1, 2021
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.Journal of medicinal chemistry, , 01-09, Volume: 63, Issue:1, 2020
Discovery of 3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-N-phenylpiperidine-1-carboxamide as novel potent analgesic.European journal of medicinal chemistry, , Mar-01, Volume: 189, 2020
Developing Cyclic Opioid Analogues: Fluorescently Labeled Bioconjugates of Biphalin.ACS medicinal chemistry letters, , May-14, Volume: 11, Issue:5, 2020
Potent, Efficacious, and Stable Cyclic Opioid Peptides with Long Lasting Antinociceptive Effect after Peripheral Administration.Journal of medicinal chemistry, , 03-12, Volume: 63, Issue:5, 2020
Novel Cyclic Biphalin Analogues by Ruthenium-Catalyzed Ring Closing Metathesis: ACS medicinal chemistry letters, , Apr-11, Volume: 10, Issue:4, 2019
[no title available]Journal of medicinal chemistry, , 12-26, Volume: 62, Issue:24, 2019
7β-Methyl substituent is a structural locus associated with activity cliff for nepenthone analogues.Bioorganic & medicinal chemistry, , 08-07, Volume: 26, Issue:14, 2018
Constraining Endomorphin-1 by β,α-Hybrid Dipeptide/Heterocycle Scaffolds: Identification of a Novel κ-Opioid Receptor Selective Partial Agonist.Journal of medicinal chemistry, , 07-12, Volume: 61, Issue:13, 2018
Discovery, structure-activity relationship studies, and anti-nociceptive effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)benzamides as novel opioid receptor agonists.European journal of medicinal chemistry, , Jan-27, Volume: 126, 2017
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CHBioorganic & medicinal chemistry, , 01-15, Volume: 25, Issue:2, 2017
Opioid Receptor Modulators with a Cinnamyl Group.Journal of medicinal chemistry, , 08-10, Volume: 60, Issue:15, 2017
Design, synthesis and biological evaluation of novel tetrahydroisoquinoline quaternary derivatives as peripheral κ-opioid receptor agonists.Bioorganic & medicinal chemistry, , 07-01, Volume: 24, Issue:13, 2016
Versatile Picklocks To Access All Opioid Receptors: Tuning the Selectivity and Functional Profile of the Cyclotetrapeptide c[Phe-d-Pro-Phe-Trp] (CJ-15,208).Journal of medicinal chemistry, , 10-13, Volume: 59, Issue:19, 2016
Evaluation of N-substituent structural variations in opioid receptor profile of LP1.Bioorganic & medicinal chemistry, , 06-15, Volume: 24, Issue:12, 2016
Probes for narcotic receptor mediated phenomena 49. N-substituted rac-cis-4a-arylalkyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.European journal of medicinal chemistry, , Mar-06, Volume: 92, 2015
Synthesis of tripeptides containing D-Trp substituted at the indole ring, assessment of opioid receptor binding and in vivo central antinociception.Journal of medicinal chemistry, , Aug-14, Volume: 57, Issue:15, 2014
Discovery, structure-activity relationship studies, and anti-nociceptive effects of 1-phenyl-3,6,6-trimethyl-1,5,6,7-tetrahydro-4H-indazol-4-one as novel opioid receptor agonists.Bioorganic & medicinal chemistry, , Sep-01, Volume: 22, Issue:17, 2014
Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.European journal of medicinal chemistry, , Volume: 63, 2013
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 9: Synthesis, characterization and molecular modeling of pyridinyl isosteres of N-BPE-8-CAC (1), a high affinity ligand for opioid receptors.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 23, Issue:7, 2013
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.Bioorganic & medicinal chemistry, , May-15, Volume: 21, Issue:10, 2013
Opioid activity profiles of oversimplified peptides lacking in the protonable N-terminus.Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 22, Issue:24, 2012
Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012
Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.Journal of medicinal chemistry, , Apr-26, Volume: 55, Issue:8, 2012
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists.Bioorganic & medicinal chemistry, , Jun-15, Volume: 18, Issue:12, 2010
Conformationally constrained kappa receptor agonists: stereoselective synthesis and pharmacological evaluation of 6,8-diazabicyclo[3.2.2]nonane derivatives.Journal of medicinal chemistry, , May-27, Volume: 53, Issue:10, 2010
Synthesis and biological evaluation of C-2 halogenated analogs of salvinorin A.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 20, Issue:19, 2010
Syntheses of novel high affinity ligands for opioid receptors.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 19, Issue:1, 2009
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants of cyclazocine.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 19, Issue:2, 2009
Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic efficacy against morphine dependence.Bioorganic & medicinal chemistry, , Aug-15, Volume: 17, Issue:16, 2009
Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.Bioorganic & medicinal chemistry, , Feb-01, Volume: 17, Issue:3, 2009
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.Journal of medicinal chemistry, , Nov-27, Volume: 51, Issue:22, 2008
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.Journal of medicinal chemistry, , Jul-24, Volume: 51, Issue:14, 2008
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine.Bioorganic & medicinal chemistry, , May-15, Volume: 16, Issue:10, 2008
Herkinorin analogues with differential beta-arrestin-2 interactions.Journal of medicinal chemistry, , Apr-24, Volume: 51, Issue:8, 2008
Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.Bioorganic & medicinal chemistry, , Feb-01, Volume: 16, Issue:3, 2008
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC.Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 17, Issue:23, 2007
In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.Bioorganic & medicinal chemistry, , Jun-15, Volume: 15, Issue:12, 2007
High-affinity carbamate analogues of morphinan at opioid receptors.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 17, Issue:6, 2007
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.Journal of medicinal chemistry, , May-03, Volume: 50, Issue:9, 2007
Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18).Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 16, Issue:17, 2006
Synthesis and in vitro pharmacological studies of new C(4)-modified salvinorin A analogues.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 16, Issue:21, 2006
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine.Journal of medicinal chemistry, , Sep-07, Volume: 49, Issue:18, 2006
Synthesis and in vitro pharmacological studies of C(4) modified salvinorin A analogues.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 15, Issue:19, 2005
Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2).Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.Journal of medicinal chemistry, , Nov-20, Volume: 46, Issue:24, 2003
Design, synthesis, and evaluation of opioid analogues with non-peptidic beta-turn scaffold: enkephalin and endomorphin mimetics.Journal of medicinal chemistry, , Mar-28, Volume: 45, Issue:7, 2002
[Pro(3)]Dyn A(1-11)-NH(2): a dynorphin analogue with high selectivity for the kappa opioid receptor.Journal of medicinal chemistry, , Jul-13, Volume: 43, Issue:14, 2000
A potent new class of kappa-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines.Journal of medicinal chemistry, , Jul-23, Volume: 36, Issue:15, 1993
New kappa-receptor agonists based upon a 2-[(alkylamino)methyl]piperidine nucleus.Journal of medicinal chemistry, , Feb-07, Volume: 35, Issue:3, 1992
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 18, Issue:13, 2008
Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 18, Issue:12, 2008
Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity.Bioorganic & medicinal chemistry letters, , May-16, Volume: 15, Issue:10, 2005
Amino acid conjugates as kappa opioid receptor agonists.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 15, Issue:5, 2005
Arylacetamides as peripherally restricted kappa opioid receptor agonists.Bioorganic & medicinal chemistry letters, , Nov-20, Volume: 10, Issue:22, 2000
Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif.Bioorganic & medicinal chemistry, , Jul-15, Volume: 23, Issue:14, 2015
Antagonists of the kappa opioid receptor.Bioorganic & medicinal chemistry letters, , May-01, Volume: 24, Issue:9, 2014
Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs.Journal of medicinal chemistry, , Apr-10, Volume: 51, Issue:7, 2008
The power of visual imagery in drug design. Isopavines as a new class of morphinomimetics and their human opioid receptor binding activity.Journal of medicinal chemistry, , Jan-02, Volume: 46, Issue:1, 2003
The "Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.Journal of medicinal chemistry, , 10-13, Volume: 59, Issue:19, 2016
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 19, Issue:1, 2009
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.Bioorganic & medicinal chemistry, , Sep-15, Volume: 17, Issue:18, 2009
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008
Tactical Approaches to Interconverting GPCR Agonists and Antagonists.Journal of medicinal chemistry, , Feb-11, Volume: 59, Issue:3, 2016
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 19, Issue:1, 2009
[no title available]Journal of natural products, , 03-26, Volume: 84, Issue:3, 2021
Structure-Activity Relationships of [des-ArgJournal of medicinal chemistry, , 11-23, Volume: 59, Issue:22, 2016
Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors.Journal of medicinal chemistry, , Nov-13, Volume: 57, Issue:21, 2014
Probes for narcotic receptor mediated phenomena. Part 42: synthesis and in vitro pharmacological characterization of the N-methyl and N-phenethyl analogues of the racemic ortho-c and para-c oxide-bridged phenylmorphans.Bioorganic & medicinal chemistry, , Jun-01, Volume: 19, Issue:11, 2011
Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.Bioorganic & medicinal chemistry, , May-01, Volume: 19, Issue:9, 2011
Synthesis and opioid activity of enantiomeric N-substituted 2,3,4,4a,5,6,7,7a-octahydro-1H-benzofuro[3,2-e]isoquinolines.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Conformationally constrained kappa receptor agonists: stereoselective synthesis and pharmacological evaluation of 6,8-diazabicyclo[3.2.2]nonane derivatives.Journal of medicinal chemistry, , May-27, Volume: 53, Issue:10, 2010
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 19, Issue:1, 2009
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.Bioorganic & medicinal chemistry, , Jul-15, Volume: 17, Issue:14, 2009
Novel trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 18, Issue:6, 2008
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.Journal of medicinal chemistry, , May-03, Volume: 50, Issue:9, 2007
Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists.Journal of medicinal chemistry, , Dec-14, Volume: 49, Issue:25, 2006
Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.Journal of medicinal chemistry, , Dec-14, Volume: 49, Issue:25, 2006
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.Journal of medicinal chemistry, , Nov-03, Volume: 48, Issue:22, 2005
trans-3,4-dimethyl-4-(3-carboxamidophenyl)piperidines: a novel class of micro-selective opioid antagonists.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 13, Issue:24, 2003
Structure-activity relationships of dynorphin a analogues modified in the address sequence.Journal of medicinal chemistry, , May-22, Volume: 46, Issue:11, 2003
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.Journal of medicinal chemistry, , Oct-11, Volume: 44, Issue:21, 2001
Design, synthesis and biological evaluation of 3-amino-3-phenylpropionamide derivatives as novel mu opioid receptor ligands.Bioorganic & medicinal chemistry letters, , Mar-20, Volume: 10, Issue:6, 2000
Electrophilic opioid ligands. Oxygen tethered alpha-methylene-gamma-lactone, acrylate, isothiocyanate, and epoxide derivatives of 6 beta-naltrexol.Journal of medicinal chemistry, , Jun-26, Volume: 35, Issue:13, 1992
N-substituent modulation of opiate agonist/antagonist activity in resolved 3-methyl-3-(m-hydroxyphenyl)piperidines.Journal of medicinal chemistry, , Volume: 29, Issue:4, 1986
3-Hydroxy-17-aralkylmorphinans as potential opiate receptor-site-directed alkylating agents.Journal of medicinal chemistry, , Volume: 20, Issue:8, 1977
[no title available],
Discovery of an Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.Journal of medicinal chemistry, , 02-27, Volume: 63, Issue:4, 2020
Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.Journal of medicinal chemistry, , 04-25, Volume: 62, Issue:8, 2019
Tactical Approaches to Interconverting GPCR Agonists and Antagonists.Journal of medicinal chemistry, , Feb-11, Volume: 59, Issue:3, 2016
Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.Journal of medicinal chemistry, , 12-22, Volume: 59, Issue:24, 2016
Probes for narcotic receptor mediated phenomena 49. N-substituted rac-cis-4a-arylalkyl-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.European journal of medicinal chemistry, , Mar-06, Volume: 92, 2015
Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 23, Issue:17, 2013
Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.Journal of medicinal chemistry, , Mar-14, Volume: 56, Issue:5, 2013
Probes for narcotic receptor mediated phenomena. 48. C7- and C8-substituted 5-phenylmorphan opioids from diastereoselective alkylation.European journal of medicinal chemistry, , Volume: 67, 2013
Probes for narcotic receptor mediated phenomena. 47. Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.Bioorganic & medicinal chemistry, , Jun-01, Volume: 21, Issue:11, 2013
Synthesis and biological evaluation of an orally active glycosylated endomorphin-1.Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012
Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity.European journal of medicinal chemistry, , Volume: 50, 2012
Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.Journal of medicinal chemistry, , Apr-26, Volume: 55, Issue:8, 2012
Synthesis and pharmacological activities of 6-glycine substituted 14-phenylpropoxymorphinans, a novel class of opioids with high opioid receptor affinities and antinociceptive potencies.Journal of medicinal chemistry, , Feb-24, Volume: 54, Issue:4, 2011
Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists.Bioorganic & medicinal chemistry, , Jun-15, Volume: 18, Issue:12, 2010
Synthesis and opioid activity of enantiomeric N-substituted 2,3,4,4a,5,6,7,7a-octahydro-1H-benzofuro[3,2-e]isoquinolines.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Highly selective and potent mu opioid ligands by unexpected substituent on morphine skeleton.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 20, Issue:1, 2010
14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs.Journal of medicinal chemistry, , Apr-10, Volume: 51, Issue:7, 2008
Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.Journal of medicinal chemistry, , Aug-24, Volume: 49, Issue:17, 2006
Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.Journal of medicinal chemistry, , Jan-12, Volume: 49, Issue:1, 2006
2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.Journal of medicinal chemistry, , Apr-08, Volume: 47, Issue:8, 2004
The power of visual imagery in drug design. Isopavines as a new class of morphinomimetics and their human opioid receptor binding activity.Journal of medicinal chemistry, , Jan-02, Volume: 46, Issue:1, 2003
Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.Journal of medicinal chemistry, , Apr-24, Volume: 46, Issue:9, 2003
Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003
Synthesis and structure--activity relationship of novel aminotetralin derivatives with high micro selective opioid affinity.Bioorganic & medicinal chemistry letters, , Nov-04, Volume: 12, Issue:21, 2002
Synthesis and biological activities of cyclic lanthionine enkephalin analogues: delta-opioid receptor selective ligands.Journal of medicinal chemistry, , Aug-15, Volume: 45, Issue:17, 2002
Synthesis and biological activity of a novel methylamine-bridged enkephalin analogue (MABE): a new route to cyclic peptides and peptidomimetics.Journal of medicinal chemistry, , Jul-02, Volume: 41, Issue:14, 1998
Phenylmorphans and analogues: opioid receptor subtype selectivity and effect of conformation on activity.Journal of medicinal chemistry, , May-01, Volume: 35, Issue:9, 1992
Highly selective kappa-opioid analgesics. 2. Synthesis and structure-activity relationships of novel N-[(2-aminocyclohexyl)aryl]acetamide derivatives.Journal of medicinal chemistry, , Volume: 32, Issue:7, 1989
Synthesis and biological activity of fluoroalkylamine derivatives of narcotic analgesics.Journal of medicinal chemistry, , Volume: 23, Issue:9, 1980
Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives.Bioorganic & medicinal chemistry, , 08-15, Volume: 25, Issue:16, 2017
Synthesis and evaluation of novel opioid ligands with a C-homomorphinan skeleton.Bioorganic & medicinal chemistry, , 05-15, Volume: 24, Issue:10, 2016
Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.Journal of medicinal chemistry, , Mar-12, Volume: 52, Issue:5, 2009
14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 19, Issue:6, 2009
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.Journal of medicinal chemistry, , 02-10, Volume: 65, Issue:3, 2022
Synthesis and biological evaluation of an orally active glycosylated endomorphin-1.Journal of medicinal chemistry, , Jun-28, Volume: 55, Issue:12, 2012
Structure-activity study on the Phe side chain arrangement of endomorphins using conformationally constrained analogues.Journal of medicinal chemistry, , Jan-29, Volume: 47, Issue:3, 2004
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.Journal of medicinal chemistry, , 02-10, Volume: 65, Issue:3, 2022
[no title available]European journal of medicinal chemistry, , Oct-01, Volume: 179, 2019
cis-4-amino-L-proline residue as a scaffold for the synthesis of cyclic and linear endomorphin-2 analogues: part 2.Journal of medicinal chemistry, , Oct-11, Volume: 55, Issue:19, 2012
Structure-activity study on the Phe side chain arrangement of endomorphins using conformationally constrained analogues.Journal of medicinal chemistry, , Jan-29, Volume: 47, Issue:3, 2004
Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor.Journal of medicinal chemistry, , Jun-14, Volume: 55, Issue:11, 2012
A new synthesis of the ORL-1 antagonist 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidinyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one (J-113397) and activity in a calcium mobilization assay.Bioorganic & medicinal chemistry, , Jan-15, Volume: 16, Issue:2, 2008
Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity.Journal of medicinal chemistry, , Feb-09, Volume: 49, Issue:3, 2006
Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).Journal of medicinal chemistry, , Dec-16, Volume: 42, Issue:25, 1999
Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Syntheses of novel high affinity ligands for opioid receptors.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.Journal of medicinal chemistry, , May-03, Volume: 50, Issue:9, 2007
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.Journal of medicinal chemistry, , Oct-11, Volume: 44, Issue:21, 2001
[no title available],
Synthesis and pharmacological evaluation of bivalent antagonists of the nociceptin opioid receptor.European journal of medicinal chemistry, , Volume: 46, Issue:4, 2011
Probing opioid receptor interactions with azacycloalkane amino acids. Synthesis of a potent and selective ORL1 antagonist.Journal of medicinal chemistry, , Nov-21, Volume: 45, Issue:24, 2002
4-Aminoquinolines: novel nociceptin antagonists with analgesic activity.Journal of medicinal chemistry, , Nov-30, Volume: 43, Issue:24, 2000
Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.Journal of medicinal chemistry, , Apr-26, Volume: 55, Issue:8, 2012
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 18, Issue:16, 2008
High-affinity carbamate analogues of morphinan at opioid receptors.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 17, Issue:6, 2007
Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.Journal of medicinal chemistry, , Jan-12, Volume: 49, Issue:1, 2006
2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.Journal of medicinal chemistry, , Apr-08, Volume: 47, Issue:8, 2004
The power of visual imagery in drug design. Isopavines as a new class of morphinomimetics and their human opioid receptor binding activity.Journal of medicinal chemistry, , Jan-02, Volume: 46, Issue:1, 2003
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.Journal of medicinal chemistry, , Nov-20, Volume: 46, Issue:24, 2003
Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.Journal of medicinal chemistry, , Apr-26, Volume: 55, Issue:8, 2012
Aminothiazolomorphinans with mixed κ and μ opioid activity.Journal of medicinal chemistry, , Mar-24, Volume: 54, Issue:6, 2011
Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.Journal of medicinal chemistry, , Jan-14, Volume: 53, Issue:1, 2010
In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.Bioorganic & medicinal chemistry, , Jun-15, Volume: 15, Issue:12, 2007
High-affinity carbamate analogues of morphinan at opioid receptors.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 17, Issue:6, 2007
Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.Journal of medicinal chemistry, , Jan-12, Volume: 49, Issue:1, 2006
2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.Journal of medicinal chemistry, , Apr-08, Volume: 47, Issue:8, 2004
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.Journal of medicinal chemistry, , Nov-20, Volume: 46, Issue:24, 2003
Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists.Bioorganic & medicinal chemistry, , Aug-01, Volume: 22, Issue:15, 2014
Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.Journal of medicinal chemistry, , Nov-27, Volume: 56, Issue:22, 2013
Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 23, Issue:13, 2013
Tetrahydroquinoline derivatives as opioid receptor antagonists.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 21, Issue:2, 2011
1-Substituted 4-(3-Hydroxyphenyl)piperazines Are Pure Opioid Receptor Antagonists.ACS medicinal chemistry letters, , Oct-14, Volume: 1, Issue:7, 2010
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 19, Issue:1, 2009
Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.Journal of medicinal chemistry, , Mar-12, Volume: 52, Issue:5, 2009
Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.Bioorganic & medicinal chemistry, , Sep-15, Volume: 17, Issue:18, 2009
14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 19, Issue:6, 2009
Syntheses of novel high affinity ligands for opioid receptors.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009
14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008
Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.Journal of medicinal chemistry, , May-03, Volume: 50, Issue:9, 2007
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.Journal of natural products, , Volume: 70, Issue:8, 2007
Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 17, Issue:24, 2007
Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 17, Issue:19, 2007
Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists.Journal of medicinal chemistry, , Dec-14, Volume: 49, Issue:25, 2006
Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.Journal of medicinal chemistry, , Dec-14, Volume: 49, Issue:25, 2006
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.Journal of medicinal chemistry, , Aug-24, Volume: 49, Issue:17, 2006
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring.Journal of medicinal chemistry, , Oct-05, Volume: 49, Issue:20, 2006
N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.Journal of medicinal chemistry, , Dec-29, Volume: 48, Issue:26, 2005
Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 15, Issue:8, 2005
Identification of a new scaffold for opioid receptor antagonism based on the 2-amino-1,1-dimethyl-7-hydroxytetralin pharmacophore.Journal of medicinal chemistry, , Oct-07, Volume: 47, Issue:21, 2004
Opioid binding and in vitro profiles of a series of 4-hdroxy-3-methoxyindolomorphinans. Transformation of a delta-selective ligand into a high affinity kappa-selective ligand by introduction of a 5,14-substituted bridge.Journal of medicinal chemistry, , Jul-03, Volume: 46, Issue:14, 2003
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.Journal of medicinal chemistry, , Apr-10, Volume: 46, Issue:8, 2003
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.Journal of medicinal chemistry, , Mar-15, Volume: 44, Issue:6, 2001
N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.Journal of medicinal chemistry, , Oct-08, Volume: 41, Issue:21, 1998
Isothiocyanate-substituted benzyl ether opioid receptor ligands derived from 6 beta-naltrexol.Journal of medicinal chemistry, , Feb-03, Volume: 38, Issue:3, 1995
Synthesis and opioid receptor affinity of a series of aralkyl ethers of 6 alpha- and 6 beta-naltrexol.Journal of medicinal chemistry, , Dec-09, Volume: 37, Issue:25, 1994
Probes for narcotic receptor mediated phenomena. 18. Epimeric 6 alpha- and 6 beta-iodo-3,14-dihydroxy-17-(cyclopropylmethyl)-4,5 alpha-epoxymorphinans as potential ligands for opioid receptor single photon emission computed tomography: synthesis, evaluatiJournal of medicinal chemistry, , Jul-24, Volume: 35, Issue:15, 1992
Electrophilic opioid ligands. Oxygen tethered alpha-methylene-gamma-lactone, acrylate, isothiocyanate, and epoxide derivatives of 6 beta-naltrexol.Journal of medicinal chemistry, , Jun-26, Volume: 35, Issue:13, 1992
[no title available],
Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.Bioorganic & medicinal chemistry, , May-01, Volume: 19, Issue:9, 2011
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 19, Issue:1, 2009
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 18, Issue:16, 2008
Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.Journal of medicinal chemistry, , 12-22, Volume: 59, Issue:24, 2016
Structural Requirements for CNS Active Opioid Glycopeptides.Journal of medicinal chemistry, , Aug-13, Volume: 58, Issue:15, 2015
Access to 7β-analogs of codeine with mixed μ/δ agonist activity via 6,7-α-epoxide opening.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 23, Issue:17, 2013
Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.Journal of medicinal chemistry, , Oct-13, Volume: 54, Issue:19, 2011
Synthesis and opioid activity of enantiomeric N-substituted 2,3,4,4a,5,6,7,7a-octahydro-1H-benzofuro[3,2-e]isoquinolines.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
1,3-Dihydro-2,1,3-benzothiadiazol-2,2-diones and 3,4-dihydro-1H-2,1,3-benzothidiazin-2,2-diones as ligands for the NOP receptor.Bioorganic & medicinal chemistry letters, , Oct-18, Volume: 14, Issue:20, 2004
New scaffolds in the development of mu opioid-receptor ligands.Bioorganic & medicinal chemistry letters, , May-05, Volume: 13, Issue:9, 2003
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.Journal of medicinal chemistry, , Apr-10, Volume: 46, Issue:8, 2003
Synthesis and biological activity of a novel methylamine-bridged enkephalin analogue (MABE): a new route to cyclic peptides and peptidomimetics.Journal of medicinal chemistry, , Jul-02, Volume: 41, Issue:14, 1998
Synthesis and Evaluation of a Novel Bivalent Selective Antagonist for the Mu-Delta Opioid Receptor Heterodimer that Reduces Morphine Withdrawal in Mice.Journal of medicinal chemistry, , Jul-26, Volume: 61, Issue:14, 2018
Novel fluoroalkyl derivatives of selective kappa opioid receptor antagonist JDTic: Design, synthesis, pharmacology and molecular modeling studies.European journal of medicinal chemistry, , Jan-27, Volume: 90, 2015
Potency enhancement of the κ-opioid receptor antagonist probe ML140 through sulfonamide constraint utilizing a tetrahydroisoquinoline motif.Bioorganic & medicinal chemistry, , Jul-15, Volume: 23, Issue:14, 2015
Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents.Bioorganic & medicinal chemistry, , Oct-01, Volume: 23, Issue:19, 2015
Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists.Bioorganic & medicinal chemistry, , Aug-01, Volume: 22, Issue:15, 2014
Development of κ opioid receptor antagonists.Journal of medicinal chemistry, , Mar-28, Volume: 56, Issue:6, 2013
Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2-methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists.Journal of medicinal chemistry, , Jun-13, Volume: 56, Issue:11, 2013
Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer.Journal of medicinal chemistry, , Dec-08, Volume: 54, Issue:23, 2011
Probes for narcotic receptor mediated phenomena. 43. Synthesis of the ortho-a and para-a, and improved synthesis and optical resolution of the ortho-b and para-b oxide-bridged phenylmorphans: compounds with moderate to low opioid-receptor affinity.Bioorganic & medicinal chemistry, , Jul-15, Volume: 19, Issue:14, 2011
Probes for narcotic receptor mediated phenomena. Part 42: synthesis and in vitro pharmacological characterization of the N-methyl and N-phenethyl analogues of the racemic ortho-c and para-c oxide-bridged phenylmorphans.Bioorganic & medicinal chemistry, , Jun-01, Volume: 19, Issue:11, 2011
Generation of novel radiolabeled opiates through site-selective iodination.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 21, Issue:13, 2011
Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242).Journal of medicinal chemistry, , Aug-25, Volume: 54, Issue:16, 2011
Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity.Journal of medicinal chemistry, , Jul-22, Volume: 53, Issue:14, 2010
Conformationally constrained kappa receptor agonists: stereoselective synthesis and pharmacological evaluation of 6,8-diazabicyclo[3.2.2]nonane derivatives.Journal of medicinal chemistry, , May-27, Volume: 53, Issue:10, 2010
Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 20, Issue:19, 2010
SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 20, Issue:18, 2010
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 19, Issue:1, 2009
Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).Journal of medicinal chemistry, , Dec-10, Volume: 52, Issue:23, 2009
Probes for narcotic receptor mediated phenomena. 37. Synthesis and opioid binding affinity of the final pair of oxide-bridged phenylmorphans, the ortho- and para-b-isomers and their N-phenethyl analogues, and the synthesis of the N-phenethyl analogues of Journal of medicinal chemistry, , Dec-25, Volume: 51, Issue:24, 2008
Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphJournal of medicinal chemistry, , Aug-09, Volume: 50, Issue:16, 2007
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Calpha,alpha-dialkylated amino acids.Bioorganic & medicinal chemistry, , Jul-01, Volume: 15, Issue:13, 2007
Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.Journal of natural products, , Volume: 70, Issue:8, 2007
N-substituted 4beta-methyl-5-(3-hydroxyphenyl)-7alpha-amidomorphans are potent, selective kappa opioid receptor antagonists.Journal of medicinal chemistry, , Mar-09, Volume: 49, Issue:5, 2006
N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.Journal of medicinal chemistry, , Dec-29, Volume: 48, Issue:26, 2005
Major effect of pyrrolic N-benzylation in norbinaltorphimine, the selective kappa-opioid receptor antagonist.Journal of medicinal chemistry, , Mar-10, Volume: 48, Issue:5, 2005
Identification of a new scaffold for opioid receptor antagonism based on the 2-amino-1,1-dimethyl-7-hydroxytetralin pharmacophore.Journal of medicinal chemistry, , Oct-07, Volume: 47, Issue:21, 2004
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.Journal of medicinal chemistry, , Apr-10, Volume: 46, Issue:8, 2003
2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy.Journal of medicinal chemistry, , May-08, Volume: 46, Issue:10, 2003
Guanidino N-substituted and N,N-disubstituted derivatives of the kappa-opioid antagonist GNTI.Journal of medicinal chemistry, , Dec-04, Volume: 46, Issue:25, 2003
The role of the side chain in determining relative delta- and kappa-affinity in C5'-substituted analogues of naltrindole.Journal of medicinal chemistry, , Jan-16, Volume: 46, Issue:2, 2003
Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.Journal of medicinal chemistry, , Jul-03, Volume: 46, Issue:14, 2003
Structure-activity relationships of dynorphin a analogues modified in the address sequence.Journal of medicinal chemistry, , May-22, Volume: 46, Issue:11, 2003
Discovery of an opioid kappa receptor selective pure antagonist from a library of N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphans.Journal of medicinal chemistry, , Aug-01, Volume: 45, Issue:16, 2002
Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity.Journal of medicinal chemistry, , Aug-16, Volume: 44, Issue:17, 2001
[Pro(3)]Dyn A(1-11)-NH(2): a dynorphin analogue with high selectivity for the kappa opioid receptor.Journal of medicinal chemistry, , Jul-13, Volume: 43, Issue:14, 2000
Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists.Journal of medicinal chemistry, , Apr-20, Volume: 43, Issue:8, 2000
Selective kappa-opioid antagonists related to naltrindole. Effect of side-chain spacer in the 5'-amidinoalkyl series.Bioorganic & medicinal chemistry letters, , Oct-16, Volume: 10, Issue:20, 2000
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 19, Issue:1, 2009
Synthesis and opioid receptor affinity of a series of aralkyl ethers of 6 alpha- and 6 beta-naltrexol.Journal of medicinal chemistry, , Dec-09, Volume: 37, Issue:25, 1994
Electrophilic opioid ligands. Oxygen tethered alpha-methylene-gamma-lactone, acrylate, isothiocyanate, and epoxide derivatives of 6 beta-naltrexol.Journal of medicinal chemistry, , Jun-26, Volume: 35, Issue:13, 1992
Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.Journal of medicinal chemistry, , 11-22, Volume: 60, Issue:22, 2017
Multitarget opioid ligands in pain relief: New players in an old game.European journal of medicinal chemistry, , Jan-27, Volume: 108, 2016
Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.Journal of medicinal chemistry, , Apr-24, Volume: 46, Issue:9, 2003
5'-halogenated analogs of oxymorphindole.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 17, Issue:21, 2007
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.Journal of medicinal chemistry, , Apr-10, Volume: 46, Issue:8, 2003
Discovery of δ opioid receptor full agonists lacking a basic nitrogen atom and their antidepressant-like effects.Bioorganic & medicinal chemistry letters, , 06-15, Volume: 30, Issue:12, 2020
Naltrindole derivatives with fluorinated ethyl substituents on the 17-nitrogen as δ opioid receptor inverse agonists.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 25, Issue:15, 2015
Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists.Bioorganic & medicinal chemistry, , Aug-01, Volume: 22, Issue:15, 2014
Synthesis and opioid receptor activity of indolopropellanes.Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 19, Issue:16, 2009
Syntheses of novel high affinity ligands for opioid receptors.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009
Highly potent and selective phenylmorphan-based inverse agonists of the opioid delta receptor.Journal of medicinal chemistry, , Sep-07, Volume: 49, Issue:18, 2006
Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.Journal of medicinal chemistry, , Dec-16, Volume: 47, Issue:26, 2004
Discovery of the first N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphan to possess highly potent and selective opioid delta receptor antagonist activity.Journal of medicinal chemistry, , Jan-15, Volume: 47, Issue:2, 2004
Identification of a new scaffold for opioid receptor antagonism based on the 2-amino-1,1-dimethyl-7-hydroxytetralin pharmacophore.Journal of medicinal chemistry, , Oct-07, Volume: 47, Issue:21, 2004
Opioid binding and in vitro profiles of a series of 4-hdroxy-3-methoxyindolomorphinans. Transformation of a delta-selective ligand into a high affinity kappa-selective ligand by introduction of a 5,14-substituted bridge.Journal of medicinal chemistry, , Jul-03, Volume: 46, Issue:14, 2003
14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.Journal of medicinal chemistry, , Apr-10, Volume: 46, Issue:8, 2003
Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as kappa-opioid receptor agonists endowed with antinociceptive and antiamnesic activity.Journal of medicinal chemistry, , Aug-28, Volume: 46, Issue:18, 2003
4'-Arylpyrrolomorphinans: effect of a pyrrolo-N-benzyl substituent in enhancing delta-opioid antagonist activity.Journal of medicinal chemistry, , Jan-17, Volume: 45, Issue:2, 2002
Derivatives of 17-(2-methylallyl)-substituted noroxymorphone: variation of the delta address and its effects on affinity and selectivity for the delta opioid receptor.Bioorganic & medicinal chemistry letters, , Nov-05, Volume: 11, Issue:21, 2001
Effect of removal of the 14-hydroxy group on the affinity of the 4,5-epoxymorphinan derivatives for orexin and opioid receptors.Bioorganic & medicinal chemistry letters, , 03-01, Volume: 59, 2022
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
Conformationally restricted κ-opioid receptor agonists: Synthesis and pharmacological evaluation of diastereoisomeric and enantiomeric decahydroquinoxalines.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 25, Issue:22, 2015
Design, synthesis, and structure-activity relationship of novel opioid κ receptor selective agonists: α-iminoamide derivatives with an azabicyclo[2.2.2]octene skeleton.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 24, Issue:21, 2014
Design and synthesis of novel opioid ligands with an azabicyclo[2.2.2]octane skeleton having a 7-amide side chain and their pharmacologies.Bioorganic & medicinal chemistry, , Jun-01, Volume: 21, Issue:11, 2013
Design and synthesis of novel opioid ligands with an azabicyclo[2.2.2]octane skeleton and their pharmacologies.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 22, Issue:8, 2012
Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.Bioorganic & medicinal chemistry, , Feb-01, Volume: 16, Issue:3, 2008
14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.Journal of medicinal chemistry, , Nov-12, Volume: 52, Issue:21, 2009
14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.Journal of medicinal chemistry, , Aug-24, Volume: 49, Issue:17, 2006
Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effects of changes to the chain linking of the C14-amino group to the aryl ring.Journal of medicinal chemistry, , Oct-05, Volume: 49, Issue:20, 2006
Discovery of an Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Conformationally restricted κ-opioid receptor agonists: Synthesis and pharmacological evaluation of diastereoisomeric and enantiomeric decahydroquinoxalines.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 25, Issue:22, 2015
Probes for narcotic receptor mediated phenomena. 47. Novel C4a- and N-substituted-1,2,3,4,4a,9a-hexahydrobenzofuro[2,3-c]pyridin-6-ols.Bioorganic & medicinal chemistry, , Jun-01, Volume: 21, Issue:11, 2013
Aminothiazolomorphinans with mixed κ and μ opioid activity.Journal of medicinal chemistry, , Mar-24, Volume: 54, Issue:6, 2011
Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.Journal of medicinal chemistry, , Jan-12, Volume: 49, Issue:1, 2006
Discovery of highly selective κ-opioid receptor agonists: 10α-Hydroxy TRK-820 derivatives.Bioorganic & medicinal chemistry letters, , 08-15, Volume: 27, Issue:16, 2017
Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies.Journal of medicinal chemistry, , 02-09, Volume: 60, Issue:3, 2017
The effect of 17-N substituents on the activity of the opioid κ receptor in nalfurafine derivatives.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 23, Issue:1, 2013
Multitarget opioid ligands in pain relief: New players in an old game.European journal of medicinal chemistry, , Jan-27, Volume: 108, 2016
Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013
Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.Journal of medicinal chemistry, , Apr-26, Volume: 55, Issue:8, 2012
Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.Bioorganic & medicinal chemistry, , May-01, Volume: 19, Issue:9, 2011
Aminothiazolomorphinans with mixed κ and μ opioid activity.Journal of medicinal chemistry, , Mar-24, Volume: 54, Issue:6, 2011
Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 20, Issue:5, 2010
Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.Journal of medicinal chemistry, , Jan-14, Volume: 53, Issue:1, 2010
Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.Journal of medicinal chemistry, , Dec-10, Volume: 52, Issue:23, 2009
Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 18, Issue:16, 2008
In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.Bioorganic & medicinal chemistry, , Jun-15, Volume: 15, Issue:12, 2007
High-affinity carbamate analogues of morphinan at opioid receptors.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 17, Issue:6, 2007
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.Journal of medicinal chemistry, , May-03, Volume: 50, Issue:9, 2007
Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.Journal of medicinal chemistry, , Jan-12, Volume: 49, Issue:1, 2006
2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.Journal of medicinal chemistry, , Apr-08, Volume: 47, Issue:8, 2004
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.Journal of medicinal chemistry, , Nov-20, Volume: 46, Issue:24, 2003
Generation of novel radiolabeled opiates through site-selective iodination.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 21, Issue:13, 2011
Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.Journal of medicinal chemistry, , Jul-03, Volume: 46, Issue:14, 2003
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.Journal of medicinal chemistry, , Mar-15, Volume: 44, Issue:6, 2001
Discovery of Potent and Selective Agonists of δ Opioid Receptor by Revisiting the "Message-Address" Concept.ACS medicinal chemistry letters, , Apr-14, Volume: 7, Issue:4, 2016
Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 19, Issue:1, 2009
Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013
A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.Journal of medicinal chemistry, , Jun-03, Volume: 47, Issue:12, 2004
Design, synthesis, and biological evaluation of (3R)-1,2,3,4-tetrahydro-7-hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-isoquinolinecarboxamide (JDTic) analogues: in vitro pharmacology and ADME profilJournal of medicinal chemistry, , Sep-11, Volume: 57, Issue:17, 2014
Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 17, Issue:24, 2007
Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 17, Issue:19, 2007
N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.Journal of medicinal chemistry, , Dec-29, Volume: 48, Issue:26, 2005
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 9: Synthesis, characterization and molecular modeling of pyridinyl isosteres of N-BPE-8-CAC (1), a high affinity ligand for opioid receptors.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 23, Issue:7, 2013
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine.Bioorganic & medicinal chemistry, , May-15, Volume: 16, Issue:10, 2008
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC.Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 17, Issue:23, 2007
Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine.Journal of medicinal chemistry, , Sep-07, Volume: 49, Issue:18, 2006
Structure-Activity Relationships of [des-ArgJournal of medicinal chemistry, , 11-23, Volume: 59, Issue:22, 2016
Structure-activity relationships of dynorphin a analogues modified in the address sequence.Journal of medicinal chemistry, , May-22, Volume: 46, Issue:11, 2003
[Pro(3)]Dyn A(1-11)-NH(2): a dynorphin analogue with high selectivity for the kappa opioid receptor.Journal of medicinal chemistry, , Jul-13, Volume: 43, Issue:14, 2000
Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.Journal of medicinal chemistry, , 12-22, Volume: 59, Issue:24, 2016
Herkinorin analogues with differential beta-arrestin-2 interactions.Journal of medicinal chemistry, , Apr-24, Volume: 51, Issue:8, 2008
Synthesis of salvinorin A analogues as opioid receptor probes.Journal of natural products, , Volume: 69, Issue:6, 2006
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands.Journal of medicinal chemistry, , Jul-28, Volume: 48, Issue:15, 2005
Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.Journal of medicinal chemistry, , 05-11, Volume: 60, Issue:9, 2017
Synthesis and biological evaluation of 2-alkyl-2-methoxymethyl-salvinorin ethers as selective κ-opioid receptor agonists.Bioorganic & medicinal chemistry letters, , Oct-15, Volume: 25, Issue:20, 2015
Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
Herkinorin analogues with differential beta-arrestin-2 interactions.Journal of medicinal chemistry, , Apr-24, Volume: 51, Issue:8, 2008
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.Journal of medicinal chemistry, , Jul-26, Volume: 50, Issue:15, 2007
Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18).Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 16, Issue:17, 2006
Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2).Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Synthesis, Biological, and Structural Explorations of New Zwitterionic Derivatives of 14- O-Methyloxymorphone, as Potent μ/δ Opioid Agonists and Peripherally Selective Antinociceptives.Journal of medicinal chemistry, , 01-24, Volume: 62, Issue:2, 2019
Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.Journal of medicinal chemistry, , 11-22, Volume: 60, Issue:22, 2017
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.Journal of medicinal chemistry, , 02-10, Volume: 65, Issue:3, 2022
Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids.Journal of medicinal chemistry, , 01-09, Volume: 63, Issue:1, 2020
From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands.Journal of medicinal chemistry, , Oct-11, Volume: 44, Issue:21, 2001
4-(p-Bromophenyl)-4-(dimethylamino)-1-phenethylcyclohexanol, an extremely potent respresentative of a new analgesic series.Journal of medicinal chemistry, , Volume: 22, Issue:10, 1979
Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.Journal of medicinal chemistry, , Oct-13, Volume: 54, Issue:19, 2011
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: deBioorganic & medicinal chemistry, , Nov-01, Volume: 18, Issue:21, 2010
Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent aJournal of medicinal chemistry, , Feb-12, Volume: 52, Issue:3, 2009
Synthesis and pharmacological evaluation of 1,2-dihydrospiro[isoquinoline-4(3H),4'-piperidin]-3-ones as nociceptin receptor agonists.Journal of medicinal chemistry, , Feb-28, Volume: 51, Issue:4, 2008
1,3-Dihydro-2,1,3-benzothiadiazol-2,2-diones and 3,4-dihydro-1H-2,1,3-benzothidiazin-2,2-diones as ligands for the NOP receptor.Bioorganic & medicinal chemistry letters, , Oct-18, Volume: 14, Issue:20, 2004
Probing opioid receptor interactions with azacycloalkane amino acids. Synthesis of a potent and selective ORL1 antagonist.Journal of medicinal chemistry, , Nov-21, Volume: 45, Issue:24, 2002
Synthesis of mixed opioid affinity cyclic endomorphin-2 analogues with fluorinated phenylalanines.ACS medicinal chemistry letters, , May-14, Volume: 6, Issue:5, 2015
Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues.Journal of medicinal chemistry, , Dec-26, Volume: 57, Issue:24, 2014
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.Journal of medicinal chemistry, , Jul-09, Volume: 52, Issue:13, 2009
Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 18, Issue:12, 2008
Synthesis, biological evaluation and structural analysis of novel peripherally active morphiceptin analogs.Bioorganic & medicinal chemistry, , Apr-01, Volume: 24, Issue:7, 2016
Structure-Activity Relationships of [des-ArgJournal of medicinal chemistry, , 11-23, Volume: 59, Issue:22, 2016
Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration.European journal of medicinal chemistry, , Feb-15, Volume: 109, 2016
Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin.Journal of medicinal chemistry, , Nov-25, Volume: 58, Issue:22, 2015
Chemotype-selective modes of action of κ-opioid receptor agonists.The Journal of biological chemistry, , Nov-29, Volume: 288, Issue:48, 2013
Isosteric replacement of acidic with neutral residues in extracellular loop-2 of the kappa-opioid receptor does not affect dynorphin A(1-13) affinity and function.Journal of medicinal chemistry, , Apr-06, Volume: 43, Issue:7, 2000
[no title available]ACS medicinal chemistry letters, , Jul-13, Volume: 8, Issue:7, 2017
Novel fluoroalkyl derivatives of selective kappa opioid receptor antagonist JDTic: Design, synthesis, pharmacology and molecular modeling studies.European journal of medicinal chemistry, , Jan-27, Volume: 90, 2015
Development of κ opioid receptor antagonists.Journal of medicinal chemistry, , Mar-28, Volume: 56, Issue:6, 2013
Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer.Journal of medicinal chemistry, , Dec-08, Volume: 54, Issue:23, 2011
Highly potent and selective phenylmorphan-based inverse agonists of the opioid delta receptor.Journal of medicinal chemistry, , Sep-07, Volume: 49, Issue:18, 2006
Discovery of the first N-substituted 4beta-methyl-5-(3-hydroxyphenyl)morphan to possess highly potent and selective opioid delta receptor antagonist activity.Journal of medicinal chemistry, , Jan-15, Volume: 47, Issue:2, 2004
Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.Journal of medicinal chemistry, , Mar-15, Volume: 44, Issue:6, 2001
7-Spiroindanyl derivatives of naltrexone and oxymorphone as selective ligands for delta opioid receptors.Journal of medicinal chemistry, , May-23, Volume: 40, Issue:11, 1997
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.Journal of medicinal chemistry, , 02-10, Volume: 65, Issue:3, 2022
Versatile Picklocks To Access All Opioid Receptors: Tuning the Selectivity and Functional Profile of the Cyclotetrapeptide c[Phe-d-Pro-Phe-Trp] (CJ-15,208).Journal of medicinal chemistry, , 10-13, Volume: 59, Issue:19, 2016
Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.Bioorganic & medicinal chemistry letters, , Jul-01, Volume: 19, Issue:13, 2009
Antagonists of the kappa opioid receptor.Bioorganic & medicinal chemistry letters, , May-01, Volume: 24, Issue:9, 2014
Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242).Journal of medicinal chemistry, , Aug-25, Volume: 54, Issue:16, 2011
Progress in the development of more effective and safer analgesics for pain management.European journal of medicinal chemistry, , Dec-01, Volume: 183, 2019
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
Seeking (and Finding) Biased Ligands of the Kappa Opioid Receptor.ACS medicinal chemistry letters, , Jul-13, Volume: 8, Issue:7, 2017
Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 26, Issue:3, 2016
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 23, Issue:11, 2013
[no title available]European journal of medicinal chemistry, , Jan-15, Volume: 228, 2022
Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain.Journal of medicinal chemistry, , Oct-24, Volume: 56, Issue:20, 2013
Progress in the development of more effective and safer analgesics for pain management.European journal of medicinal chemistry, , Dec-01, Volume: 183, 2019
Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.Journal of medicinal chemistry, , Nov-26, Volume: 55, Issue:22, 2012
Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.Journal of medicinal chemistry, , 02-10, Volume: 65, Issue:3, 2022
Progress in the development of more effective and safer analgesics for pain management.European journal of medicinal chemistry, , Dec-01, Volume: 183, 2019
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.Journal of medicinal chemistry, , 11-21, Volume: 61, Issue:22, 2018
Kappa-opioid receptor-selective dicarboxylic ester-derived salvinorin A ligands.Bioorganic & medicinal chemistry letters, , May-15, Volume: 23, Issue:10, 2013
Enables
This protein enables 5 target(s):
| Target | Category | Definition |
|---|
| G protein-coupled opioid receptor activity | molecular function | Combining with an opioid (any narcotic derived from or resembling opium), and transmitting the signal across the membrane by activating an associated G-protein. [GOC:ai, GOC:bf, PMID:20494127] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| receptor serine/threonine kinase binding | molecular function | Binding to a receptor that possesses protein serine/threonine kinase activity. [GOC:mah] |
| dynorphin receptor activity | molecular function | Combining with a dynorphin peptide, and transmitting the signal across the membrane by activating an associated G-protein. Dynorphin is any opioid peptide that is generated by cleavage of the precursor protein prodynorphin. [GOC:bf, Wikipedia:Dynorphin] |
| neuropeptide binding | molecular function | Interacting selectively and non-covalently and stoichiometrically with neuropeptides, peptides with direct synaptic effects (peptide neurotransmitters) or indirect modulatory effects on the nervous system (peptide neuromodulators). [http://www.wormbook.org/chapters/www_neuropeptides/neuropeptides.html] |
Located In
This protein is located in 13 target(s):
| Target | Category | Definition |
|---|
| nucleoplasm | cellular component | That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653] |
| mitochondrion | cellular component | A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration. [GOC:giardia, ISBN:0198506732] |
| cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| membrane | cellular component | A lipid bilayer along with all the proteins and protein complexes embedded in it and attached to it. [GOC:dos, GOC:mah, ISBN:0815316194] |
| sarcoplasmic reticulum | cellular component | A fine reticular network of membrane-limited elements that pervades the sarcoplasm of a muscle cell; continuous over large portions of the cell and with the nuclear envelope; that part of the endoplasmic reticulum specialized for calcium release, uptake and storage. [GOC:mtg_muscle, ISBN:0124325653, ISBN:0198547684] |
| T-tubule | cellular component | Invagination of the plasma membrane of a muscle cell that extends inward from the cell surface around each myofibril. The ends of T-tubules make contact with the sarcoplasmic reticulum membrane. [GOC:mtg_muscle, ISBN:0815316194] |
| dendrite | cellular component | A neuron projection that has a short, tapering, morphology. Dendrites receive and integrate signals from other neurons or from sensory stimuli, and conduct nerve impulses towards the axon or the cell body. In most neurons, the impulse is conveyed from dendrites to axon via the cell body, but in some types of unipolar neuron, the impulse does not travel via the cell body. [GOC:aruk, GOC:bc, GOC:dos, GOC:mah, GOC:nln, ISBN:0198506732] |
| synaptic vesicle membrane | cellular component | The lipid bilayer surrounding a synaptic vesicle. [GOC:mah] |
| presynaptic membrane | cellular component | A specialized area of membrane of the axon terminal that faces the plasma membrane of the neuron or muscle fiber with which the axon terminal establishes a synaptic junction; many synaptic junctions exhibit structural presynaptic characteristics, such as conical, electron-dense internal protrusions, that distinguish it from the remainder of the axon plasma membrane. [GOC:jl, ISBN:0815316194] |
| perikaryon | cellular component | The portion of the cell soma (neuronal cell body) that excludes the nucleus. [GOC:jl] |
| axon terminus | cellular component | Terminal inflated portion of the axon, containing the specialized apparatus necessary to release neurotransmitters. The axon terminus is considered to be the whole region of thickening and the terminal button is a specialized region of it. [GOC:dph, GOC:jl] |
| postsynaptic membrane | cellular component | A specialized area of membrane facing the presynaptic membrane on the tip of the nerve ending and separated from it by a minute cleft (the synaptic cleft). Neurotransmitters cross the synaptic cleft and transmit the signal to the postsynaptic membrane. [ISBN:0198506732] |
Active In
This protein is active in 2 target(s):
| Target | Category | Definition |
|---|
| plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
| neuron projection | cellular component | A prolongation or process extending from a nerve cell, e.g. an axon or dendrite. [GOC:jl, http://www.cogsci.princeton.edu/~wn/] |
Involved In
This protein is involved in 30 target(s):
| Target | Category | Definition |
|---|
| immune response | biological process | Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. [GO_REF:0000022, GOC:add] |
| adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | biological process | A G protein-coupled receptor signaling pathway in which the signal is transmitted via the inhibition of adenylyl cyclase activity and a subsequent decrease in the intracellular concentration of cyclic AMP (cAMP). [GOC:dph, GOC:mah, GOC:signaling, GOC:tb, ISBN:0815316194] |
| phospholipase C-activating G protein-coupled receptor signaling pathway | biological process | A G protein-coupled receptor signaling pathway in which the signal is transmitted via the activation of phospholipase C (PLC) and a subsequent increase in the intracellular concentration of inositol trisphosphate (IP3) and diacylglycerol (DAG). [GOC:dph, GOC:mah, GOC:signaling, GOC:tb, ISBN:0815316194] |
| chemical synaptic transmission | biological process | The vesicular release of classical neurotransmitter molecules from a presynapse, across a chemical synapse, the subsequent activation of neurotransmitter receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell) and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process encompasses both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse. [GOC:jl, MeSH:D009435] |
| sensory perception | biological process | The series of events required for an organism to receive a sensory stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process. [GOC:ai, GOC:dph] |
| locomotory behavior | biological process | The specific movement from place to place of an organism in response to external or internal stimuli. Locomotion of a whole organism in a manner dependent upon some combination of that organism's internal state and external conditions. [GOC:dph] |
| sensory perception of pain | biological process | The series of events required for an organism to receive a painful stimulus, convert it to a molecular signal, and recognize and characterize the signal. Pain is medically defined as the physical sensation of discomfort or distress caused by injury or illness, so can hence be described as a harmful stimulus which signals current (or impending) tissue damage. Pain may come from extremes of temperature, mechanical damage, electricity or from noxious chemical substances. This is a neurological process. [GOC:curators] |
| adenylate cyclase-inhibiting opioid receptor signaling pathway | biological process | An adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway initiated by an opioid binding to its receptor, and ending with the regulation of a downstream cellular process. [GOC:dph, GOC:mah, GOC:signaling, GOC:tb] |
| response to insulin | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insulin stimulus. Insulin is a polypeptide hormone produced by the islets of Langerhans of the pancreas in mammals, and by the homologous organs of other organisms. [GOC:mah, ISBN:0198506732] |
| positive regulation of dopamine secretion | biological process | Any process that activates or increases the frequency, rate or extent of the regulated release of dopamine. [GOC:sl] |
| negative regulation of luteinizing hormone secretion | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of luteinizing hormone. [GOC:mah] |
| response to nicotine | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a nicotine stimulus. [GOC:bf, GOC:ef, ISBN:0198506732, ISBN:0582227089] |
| G protein-coupled opioid receptor signaling pathway | biological process | A G protein-coupled receptor signaling pathway initiated by an opioid binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process. [GOC:bf, PMID:20494127] |
| maternal behavior | biological process | Female behaviors associated with the care and rearing of offspring. [GOC:curators] |
| eating behavior | biological process | The specific behavior of an organism relating to the intake of food, any substance (usually solid) that can be metabolized by an organism to give energy and build tissue. [GOC:jl, GOC:pr, PMID:19361967] |
| response to estrogen | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of stimulus by an estrogen, C18 steroid hormones that can stimulate the development of female sexual characteristics. [GOC:jl, ISBN:0198506732] |
| estrous cycle | biological process | A type of ovulation cycle, which occurs in most mammalian therian females, where the endometrium is resorbed if pregnancy does not occur. [GOC:jl, Wikipedia:Estrous_cycle] |
| response to ethanol | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ethanol stimulus. [GOC:go_curators] |
| regulation of saliva secretion | biological process | Any process that modulates the frequency, rate or extent of the regulated release of saliva from a cell or a tissue. [GOC:ai] |
| behavioral response to cocaine | biological process | Any process that results in a change in the behavior of an organism as a result of a cocaine stimulus. [GOC:jid] |
| sensory perception of temperature stimulus | biological process | The series of events required for an organism to receive a sensory temperature stimulus, convert it to a molecular signal, and recognize and characterize the signal. This is a neurological process. [GOC:ai] |
| defense response to virus | biological process | Reactions triggered in response to the presence of a virus that act to protect the cell or organism. [GOC:ai] |
| cellular response to lipopolysaccharide | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria. [GOC:mah] |
| cellular response to glucose stimulus | biological process | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glucose stimulus. [GOC:mah] |
| positive regulation of p38MAPK cascade | biological process | Any process that activates or increases the frequency, rate or extent of p38MAPK cascade. [GOC:TermGenie] |
| positive regulation of potassium ion transmembrane transport | biological process | Any process that activates or increases the frequency, rate or extent of potassium ion transmembrane transport. [GOC:BHF, GOC:TermGenie] |
| response to acrylamide | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an acrylamide stimulus. [GO_REF:0000071, GOC:TermGenie, PMID:16292499] |
| positive regulation of eating behavior | biological process | Any process that activates or increases the frequency, rate or extent of eating behavior. [GO_REF:0000058, GOC:TermGenie, PMID:11961051] |
| conditioned place preference | biological process | The associative learning process by which an animal learns and remembers an association between a neutral, unchanging environment and a putatively rewarding, internal state produced by a xenobiotic or drug. [PMID:21549821] |
| neuropeptide signaling pathway | biological process | A G protein-coupled receptor signaling pathway initiated by a neuropeptide binding to its receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process. [GOC:mah, ISBN:0815316194] |